Topic: hereditary angioedema
Critics of Takeda’s $62 billion Shire buyout have fretted lately about the company’s hemophilia standing. But immunology is a different story.
Shire got a brand-new approval that could help it dominate the hereditary angioedema market for years—and rack up blockbuster sales in the process.
Shire's ability to market Cinryze for children as young as 6 with HAE. That could help Shire fend off an all-out attack from CSL.
Shire fought hard to stop it, but no dice: CSL has now launched its hereditary angioedema med Haegarda—and at a big discount, too.